Unlock stock picks and a broker-level newsfeed that powers Wall Street.

US Penny Stocks To Watch In December 2024

In This Article:

As the U.S. market anticipates the Federal Reserve's decision on interest rates, stock futures are pointing to a higher open, suggesting a potential rebound from recent downturns. For investors looking beyond large-cap stocks, penny stocks—often representing smaller or newer companies—remain an intriguing area of exploration despite their historical connotations. These stocks can offer hidden value when backed by strong financials and growth potential, and this article will highlight three such opportunities that could provide both stability and upside in today's market landscape.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

Inter & Co (NasdaqGS:INTR)

$4.39

$1.94B

★★★★☆☆

QuantaSing Group (NasdaqGM:QSG)

$3.08

$120.12M

★★★★★★

BAB (OTCPK:BABB)

$0.9075

$6.35M

★★★★★★

Imperial Petroleum (NasdaqCM:IMPP)

$2.88

$87.05M

★★★★★★

ZTEST Electronics (OTCPK:ZTST.F)

$0.2392

$8.46M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$67.38M

★★★★★★

Smith Micro Software (NasdaqCM:SMSI)

$0.9971

$15.52M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$0.859

$75.24M

★★★★★☆

Zynerba Pharmaceuticals (NasdaqCM:ZYNE)

$1.30

$65.6M

★★★★★☆

Safe Bulkers (NYSE:SB)

$3.57

$387.6M

★★★★☆☆

Click here to see the full list of 720 stocks from our US Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Lixte Biotechnology Holdings

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company dedicated to identifying targets for cancer drug development and commercializing cancer therapies, with a market cap of $4.72 million.

Operations: Lixte Biotechnology Holdings, Inc. does not currently report any revenue segments.

Market Cap: $4.72M

Lixte Biotechnology Holdings, with a market cap of US$4.72 million, is currently pre-revenue and unprofitable, facing challenges typical for penny stocks in the biotech sector. The company has less than a year of cash runway and no long-term liabilities, but its short-term assets exceed short-term liabilities by US$1.37 million. Recent amendments to its collaboration with the Netherlands Cancer Institute indicate strategic focus but also entail financial constraints with a reduced budget commitment of €100,000 annually. Lixte is working to regain Nasdaq compliance through equity offerings after failing to meet stockholders’ equity requirements, highlighting both risk and potential opportunity for investors aware of volatility and regulatory pressures inherent in such investments.